Anavex Life Sciences Corp. (AVXL) Trading 8% Higher
Anavex Life Sciences Corp. (NASDAQ:AVXL)’s share price traded up 8% during trading on Monday . The stock traded as high as $7.82 and last traded at $7.41, with a volume of 1,510,402 shares. The stock had previously closed at $6.86.
Several equities analysts have recently commented on the stock. Maxim Group restated a “buy” rating and set a $15.00 price target on shares of Anavex Life Sciences Corp. in a research report on Wednesday, May 11th. FBR & Co restated an “outperform” rating and set a $10.00 price target on shares of Anavex Life Sciences Corp. in a research report on Tuesday. Finally, Zacks Investment Research lowered shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th.
The company’s market capitalization is $260.07 million. The stock’s 50-day moving average price is $5.71 and its 200 day moving average price is $4.89.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. Equities research analysts forecast that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.